Reinforcement learning design for cancer clinical trials
Author:
Publisher
Wiley
Subject
Statistics and Probability,Epidemiology
Reference42 articles.
1. Widening bottlenecks in drug discovery Glimpses from Drug Discovery Technology Europe;Hogberg;Drug Discovery Today,2005
2. Food and Drug Administration. Innovation or stagnation: challenge and opportunity on the critical path to new medical products. White Paper, 2004.
3. Considerations for second-line therapy of non-small cell lung cancer;Stinchcombe;The Oncologist,2008
4. Evaluating multiple treatment courses in clinical trials;Thall;Statistics in Medicine,2000
5. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring;Thall;Statistics in Medicine,2007
Cited by 172 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Deep reinforcement learning control of combined chemotherapy and anti-angiogenic drug delivery for cancerous tumor treatment;Computers in Biology and Medicine;2024-10
2. Reinforcement Learning in Modern Biostatistics: Constructing Optimal Adaptive Interventions;International Statistical Review;2024-07-29
3. A guide to artificial intelligence for cancer researchers;Nature Reviews Cancer;2024-05-16
4. A model-free variable screening method for optimal treatment regimes with high-dimensional survival data;Biometrika;2024-04-25
5. Redefining Counterfactual Explanations for Reinforcement Learning: Overview, Challenges and Opportunities;ACM Computing Surveys;2024-04-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3